Floatz logo

Pamrevlumab

Liver Fibrosis Due to Chronic Hepatitis B Infection

Kyntra Biomonoclonal_antibodyPhase 2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Liver Fibrosis Due to Chronic Hepatitis B Infection cohort.

Asset / SponsorPhaseRating
Entecavir
Kyntra Bio
Phase 2CCC

Same molecule, other indications

Pamrevlumab is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
61 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
52 / 100
View asset →
Duchenne muscular dystrophyDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →